Form PTO-1449 — U.S. Department of Commerce, Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Atty. Docket No.	Serial No.
55669-A-PCT-US	09/753,169
Applicant: Cy A. Stein	
Filing Date: 01/02/01	Group: 1635

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JR	AA	5,023,243	6/11/91	Tullis, R.			
JR	AB	5,102,7065	4/21/92	Schewmaker, et al.			
	AC	5,496,547	3/96	Lam et al.			
	AD	5,587,470	12/24/96	Cook et al.			
	AE	5,593,974	1/97	Rosenberg et al.			
	AF	5,660,330	8/23/97	Cook et al.			
	AG	5,689,052	11/97	Brown et al.			
	AH	5,702,892	12/97	Reed et al.			
	AI	5,734,033	3/31/98	Reed et al.			
JR	AJ	5,770,695	7/98	Gibbons et al.			
JR	AK	5,843,733	12/98	Yoshida et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
JR	AL	9805777	02/98	WO				
JR	AM	9515400	06/95	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JR		Agrawal, S., et al., Proc. Natl. Acad. Sci. U.S.A. (1988) Vol. 85:7079-7083;
		Antisense'97: A roundtable on the state of the industry. Nature Biotechnology 15(June 1997): 519-524;
JR		Beaucage, S., and Caruthers, M., Tetrahedron Lett. (1981) Vol. 22:1859-1862;

EXAMINER: Janet Epps-Ford — DATE CONSIDERED: 6-12-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 55669-A-PCT-US	Serial No. 09/753,169
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Cy A. Stein	
	Filing Date 01/02/01	Group 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Cook, P.D., "Medicinal Chemistry of Antisense Oligonucleotides - future opportunities" (1991) Anti Cancer Drug Design Vol. 6:585--607;
	Crooke, S.T. Vitravene--Another piece in the Mosaic. Antisense and Nucleic Acid Drug Dev. 8(1998):vii-viii.
	Gewritz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on it s promise. Proc. Natl. Acad. Sci. USA 93 (April 1996); 3161-3163.
	Ghosh, S., et al., J. Biol. Chem. (1990) Vol. 265:2935-2940
	Gura, T. Antisense has growing pains. Science 270 (Oct. 1995): 575-577
	Hemken, P., et al., J. Biol. Chem. (1992) Vol. 267:9948-0057;
	Iverson, P., Anti-Cancer Drug Des. (1991) Vol. 6:531-538;
	Krajewska, M. et al. "Immunohistochemical analysis bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancer." Am. J. Pathol. (1996) Vol. 148:1567-1576;
	Luedeke, G.H., Ziegler, Al., Stahel, R.A., and Zangemeister-Wittke, U., "Antisense oligonucleotides targeting sequences shared by the Bcl-2 and the Bcl-xL mRNA efficiently downregulate expression of both proteins and induce apoptosis of lung cancer cells." Division

EXAMINER Janet Epps-Ford	DATE CONSIDERED 6-12-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 55669-A-PCT-US	Serial No. 09/753,169
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Cy A. Stein	
	Filing Date 01/02/01	Group 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	of Oncology, Department of Internal Medicine, University Hospital, CH-8091 Zurich, Switzerland. (Abstract #1140 from 88 Ann. Meet. AACR, April 12-16, 1997, Vol. 38, (March 1997), p. 171);
	Milligan et al., "Current Concepts in Antisense Drug Design" Journal of Medicinal Chemistry (July 9, 1993) Vol. 36:1924-1937;
	Pollman et al., "Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease." Nature Medicine (1998) Vol. 4:222-227;
	Ratajczak, et al., Proc. Natl. Acad. Sci. U.S.A. (1992) Vol. 89:11823;
	Rojanasakul, Y. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug delivery rev. 18(1996: 115-131.
	Stein, C.A. Keeping the biotechnology of antisense in context. Nature Biotechnology 17(March 1999):209
	Stull et al. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prosepcts. Pharm. Res. 12 (April 1995): 465-483.
	Uhlmann, E. And Peyman A., "Antisense Oligonucleotides: A New Therapeutic Principle" Chem. Rev. (1990) Vol. 90:544-579;
	Wang, Z. et al., "Induction of bcl-xl by CD40 Engagement Rescues slg-induced Apoptosis in Murine B Cells", The Journal of Immunology (1995) Vol. 155:3722-3725;

EXAMINER Janet Epps-Ford	DATE CONSIDERED 6-12-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Atty. Docket No. 55669-A-PCT-US	Serial No. 09/753,169
Applicant: Cy A. Stein	
Filing Date: 01/02/01	Group: 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JK		Zhao, Q., et al., Antisense Research and Development (1993) Vol. 3:53-66;
JK		Zon, G., "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research (November 9, 1988) Vol. 5:539-549;

EXAMINER: Janet L. Epps-Ford

DATE CONSIDERED: 6-12-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant